Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study
- PMID: 11082084
- PMCID: PMC27527
- DOI: 10.1136/bmj.321.7271.1252
Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study
Abstract
Objectives: To review the benefit of an endoscopic surveillance programme for patients with Barrett's oesophagus.
Design: Observational study.
Setting: University teaching hospital.
Participants: 409 patients in whom Barrett's oesophagus was identified during 1984-94; 143 were entered into the annual surveillance programme.
Main outcome measures: Development of dysplasia and cancer and mortality.
Results: The average period of surveillance was 4.4 years; 55 patients were reassessed in 1994 but only eight remained in the programme in 1999, withdrawal being due to death (not from carcinoma of the oesophagus), illness, or frailty. Five of the patients who entered surveillance developed carcinoma of the oesophagus. Only one cancer was identified as a result of a surveillance endoscopy, the others being detected during endoscopy to investigate altered symptoms. Of the 266 patients who were not suitable for surveillance, one died from oesophageal cancer and 103 from other causes. Surveillance has resulted in 745 endoscopies and about 3000 biopsy specimens.
Conclusion: The current surveillance strategy has limited value, and it may be appropriate to restrict surveillance to patients with additional risk factors such as stricture, ulcer, or long segment (>80 mm) Barrett's oesophagus.
Comment in
-
Barrett's oesophagus: the continuing conundrum.BMJ. 2000 Nov 18;321(7271):1238-9. doi: 10.1136/bmj.321.7271.1238. BMJ. 2000. PMID: 11082070 Free PMC article. No abstract available.
-
Surveillance for Barrett's oesophagus. The conundrum of Barrett's oesophagus is changing.BMJ. 2001 May 5;322(7294):1124-5; author reply 1126. BMJ. 2001. PMID: 11360913 Free PMC article. No abstract available.
-
Surveillance for Barrett's oesophagus. Appropriate practice must be studied.BMJ. 2001 May 5;322(7294):1125-6. BMJ. 2001. PMID: 11360914 No abstract available.
-
Surveillance for Barrett's oesophagus. It is too early to dismiss surveillance programmes.BMJ. 2001 May 5;322(7294):1125; author reply 1126. BMJ. 2001. PMID: 11360915 No abstract available.
-
Surveillance for Barrett's oesophagus. Patients need to be appropriately selected for follow up.BMJ. 2001 May 5;322(7294):1125; author reply 1126. BMJ. 2001. PMID: 11360916 No abstract available.
Similar articles
-
Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1029-35. doi: 10.1097/00042737-200510000-00005. Eur J Gastroenterol Hepatol. 2005. PMID: 16148547
-
Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance.Dis Esophagus. 2000;13(1):28-31. doi: 10.1046/j.1442-2050.2000.00069.x. Dis Esophagus. 2000. PMID: 11005328 Review.
-
A surveillance programme for Barrett's oesophagus in a UK general hospital.Eur J Gastroenterol Hepatol. 2007 Apr;19(4):305-9. doi: 10.1097/01.meg.0000252630.96043.b1. Eur J Gastroenterol Hepatol. 2007. PMID: 17353694
-
A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.Eur J Gastroenterol Hepatol. 2001 Jun;13(6):639-45. doi: 10.1097/00042737-200106000-00005. Eur J Gastroenterol Hepatol. 2001. PMID: 11434588
-
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080. Health Technol Assess. 2006. PMID: 16545207 Review.
Cited by
-
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinoma.Gut. 2024 May 10;73(6):897-909. doi: 10.1136/gutjnl-2023-331557. Gut. 2024. PMID: 38553042 Free PMC article.
-
Undetected Barrett's esophagus: how do we improve early detection?Oncotarget. 2021 Nov 23;12(24):2418-2420. doi: 10.18632/oncotarget.28005. eCollection 2021 Nov 23. Oncotarget. 2021. PMID: 34853662 Free PMC article. No abstract available.
-
Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2022 Feb;20(2):e31-e50. doi: 10.1016/j.cgh.2021.04.032. Epub 2021 Apr 23. Clin Gastroenterol Hepatol. 2022. PMID: 33901662 Free PMC article. Review.
-
A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.Dig Dis Sci. 2022 Feb;67(2):516-523. doi: 10.1007/s10620-021-06863-0. Epub 2021 Mar 13. Dig Dis Sci. 2022. PMID: 33713247 Free PMC article.
-
Establishing spectrochemical changes in the natural history of oesophageal adenocarcinoma from tissue Raman mapping analysis.Anal Bioanal Chem. 2020 Jul;412(17):4077-4087. doi: 10.1007/s00216-020-02637-1. Epub 2020 Apr 25. Anal Bioanal Chem. 2020. PMID: 32333079 Free PMC article.
References
-
- Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology. 1984;87:927–933. - PubMed
-
- Cameron AJ, Ott J, Payne WS. The incidence of adenocarcinoma in columnar lined (Barrett's) esophagus. N Engl J Med. 1985;313:857–859. - PubMed
-
- Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614–621. - PubMed
-
- Wilson JMG, Junger G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical